Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin detemir versus NPH insulin for weight change in overweight or obese adults with type 2 diabetes
2005-000976-42Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin detemir once daily plus mealtime insulin aspart with NPH insulin once daily plus mealtime insulin aspart (2 arms). Primary endpoint: Weight change during 26 weeks of treatment. Started May 2006; status: completed.
02
Drugs
insulin detemirhuman insulininsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000976-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000976-42.